Nico Löchner

[EQS News | International @eqsnews_int]

German Federal Government invests 300 Million Euros in CureVac https://t.co/texXWJGvfl

[Nico Löchner @NicoLoechner]

$FGEN Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease https://t.co/v2DLPuydGA

[Nico Löchner @NicoLoechner]

$STML MENARINI GROUP TO ACQUIRE STEMLINE THERAPEUTICS

TOTAL POTENTIAL CONSIDERATION OF $12.50 PER SHARE COMPRISING $11.50 CASH AND $1.00 CONTINGENT VALUE RIGHT

[Nico Löchner @NicoLoechner]

$AFMD Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer

https://t.co/Aj6Ro3LzhJ

[Nico Löchner @NicoLoechner]

$AFMD Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer

[Nico Löchner @NicoLoechner]

$BPMC LEERINK RAISES TARGET PRICE TO $120 FROM $103

[Nico Löchner @NicoLoechner]

$FGEN PR

FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

https://t.co/cl9vhrWyvF

[Nico Löchner @NicoLoechner]

$FGEN
-In incident dialysis patients, roxadustat had a lower risk of MACE and MACE+ and showed a trend towards lower risk of all-cause mortality relative to epoetin alfa

[Nico Löchner @NicoLoechner]

$FGEN
-In non dialysis-dependent patients receiving roxadustat, the risk of MACE, MACE+ and all-cause mortality was comparable to placebo

[Nico Löchner @NicoLoechner]

$FGEN
-Dialysis-dependent patients receiving roxadustat had a lower risk of MACE+ and no increased risk of MACE or all-cause mortality versus epoetin alfa

[Nico Löchner @NicoLoechner]

$FGEN Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators https://t.co/O06fee8Oiz

[Nico Löchner @NicoLoechner]

$FGEN

[Nico Löchner @NicoLoechner]

$FGEN halted

[Nico Löchner @NicoLoechner]

$MDCO ORION-11 STUDY MET ALL PRIMARY AND SECONDARY EFFICACY ENDPOINTS WITH EFFICACY CONSISTENT WITH PHASE 1 AND 2 STUDIES

[EM @8thKingofRome]

$AFMD Investigating Safety And Preliminary Efficacy Of Afm13 Plus Pembrolizumab In Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure https://t.co/uWlyqdbkpH

[Nico Löchner @NicoLoechner]

$AFMD decides to terminate AFM11 T cell engager Phase 1 program

[Nico Löchner @NicoLoechner]

$FGEN $AZN roxadustat

Q2'19 anaemia of CKD: data readout (pooled safety)

H2'19: anaemia of CKD: regulatory submission (US)

2020: anaemia of myelodysplastic syndrome: data readout

https://t.co/6VJ7o1xL2N

[Nico Löchner @NicoLoechner]

$HSGX Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

[Nico Löchner @NicoLoechner]

$ALNY $REGN Regeneron to Invest $800 million Through Upfront Cash and Equity Investment in Alnylam, with up to Additional $200 Million in Potential Near-Term Milestones

[Nico Löchner @NicoLoechner]

$ALNY Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases